ライフサイエンスコーパス: rhabdomyolysis

1 es (delayed nephrotoxic, delayed neurotoxic, rhabdomyolysis).

2 ed liver and muscle toxicity consistent with rhabdomyolysis.

3 regarding myopathy, which may lead to fatal rhabdomyolysis.

4 liver toxicity, and muscle toxicity without rhabdomyolysis.

5 number needed to treat, and relative risk of rhabdomyolysis.

6 and common compounds that cause drug-induced rhabdomyolysis.

7 lt in an excellent prognosis of drug-induced rhabdomyolysis.

8 otherapy substantially increased the risk of rhabdomyolysis.

9 mon pediatric drugs that are associated with rhabdomyolysis.

10 istration (FDA) reports on statin-associated rhabdomyolysis.

11 decrease renal injury after glycerol-induced rhabdomyolysis.

12 with symptoms of recurrent exercise-induced rhabdomyolysis.

13 rate climates with increasing frequency, and rhabdomyolysis.

14 issue levels and predisposing the patient to rhabdomyolysis.

15 iratory failure and acute renal failure with rhabdomyolysis.

16 homeostasis in skeletal muscle, resulting in rhabdomyolysis.

17 Failure to do so can result in rhabdomyolysis.

18 ned death in the absence of exertion-related rhabdomyolysis.

19 ed with dominant skin diseases, but not with rhabdomyolysis.

20 each with advanced liver disease, developed rhabdomyolysis.

21 from three unrelated families with recurrent rhabdomyolysis.

22 ents in the treatment group (2.6%) developed rhabdomyolysis.

23 elated symptoms and a subset are at risk for rhabdomyolysis.

24 iratory failure and acute renal failure with rhabdomyolysis.

25 including cardiomyopathy, hypoglycemia, and rhabdomyolysis.

26 n in C3 knockout mice after the induction of rhabdomyolysis.

27 stations such as haemolysis, haemorrhage and rhabdomyolysis.

28 2A2 variant and autosomal dominant recurrent rhabdomyolysis.

29 as a cause of exertion-related death without rhabdomyolysis.

30 ad following a trigger, leading to recurrent rhabdomyolysis.

31 OBSCN) predisposing individuals to recurrent rhabdomyolysis.

32 th a significantly higher risk of exertional rhabdomyolysis.

33 null mutations in the LPIN1 gene suffer from rhabdomyolysis.

34 evere acute kidney injury (AKI) secondary to rhabdomyolysis.

35 without intellectual disability, or isolated rhabdomyolysis.

36 presented with acute polymyositis leading to rhabdomyolysis.

37 n, and the neuroleptic malignant syndrome or rhabdomyolysis.

38 lovastatin contributes to increased risk of rhabdomyolysis.

39 iver enzymes, muscle aches, and very rarely, rhabdomyolysis.

40 effects ranging in severity from myalgias to rhabdomyolysis.

41 number of side effects in muscle, including rhabdomyolysis.

42 known to cause myopathy and, in rare cases, rhabdomyolysis.

43 eful monitoring due to the increased risk of rhabdomyolysis.

44 ted adverse effect with this group of drugs, rhabdomyolysis.

45 se in malignancy, transaminase elevation, or rhabdomyolysis.

46 x into the growing limb muscle fibers causes rhabdomyolysis.

47 1.9 [1.4-2.6]), hypotension (1.8 [1.3-2.3]), rhabdomyolysis (1.8 [1.3-2.3]), or dyslipidemia (2.0 [1.

48 not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10

49 with a higher risk for hospitalization with rhabdomyolysis (absolute risk increase, 0.02% [95% CI, 0

50 d through electronic screening for all-cause rhabdomyolysis admissions, followed by manual medical re

51 ase II deficiency, sometimes associated with rhabdomyolysis and acute renal injury.

52 tion and management of both pressure-induced rhabdomyolysis and anastomotic failure after bariatric s

53 L/6 mice in two translational models of AKI (rhabdomyolysis and bilateral ischemia reperfusion).

54 injury, and increased levels of apoptosis in rhabdomyolysis and cisplatin-induced AKI, despite signif

55 dels to test whether the risks of exertional rhabdomyolysis and death varied according to sickle cell

56 cell trait elevates the risks of exertional rhabdomyolysis and death.

57 tely triggers sustained muscle contractions, rhabdomyolysis and death.

58 hanges are thought to contribute to fatigue, rhabdomyolysis and disruption of excitation-contraction

59 Results were sensitive to rates of rhabdomyolysis and drug costs.

60 erse events: one (4%) of 25 each had grade 3 rhabdomyolysis and grade 2 hypothyroidism; grade 3 irido

61 describe a patient who presented with acute rhabdomyolysis and had 68% cytochrome c oxidase (COX)-de

62 is a controversial treatment of drug-induced rhabdomyolysis and has proven to be beneficial in some p

63 ported to date and only the second with both rhabdomyolysis and hemolysis.

64 eakness, with death at age 4 associated with rhabdomyolysis and hyperkalemia.

65 oglycemia, (cardio)myopathy, arrhythmia, and rhabdomyolysis and illustrates the importance of FAO dur

66 ns results in inflammatory disorders such as rhabdomyolysis and Majeed syndrome.

67 at risk for ischemia-induced organ failure, rhabdomyolysis and muscle compartment syndromes, and ven

68 ation are a common cause of exercise-induced rhabdomyolysis and myoglobinuria.

69 The risk of rhabdomyolysis and other adverse effects with statin use

70 disease, which is characterized by recurrent rhabdomyolysis and peripheral neuropathy, but without in

71 NA gene point mutation presenting with acute rhabdomyolysis and recurrent myoglobinuria.

72 nically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune

73 for oxidative injury in the renal failure of rhabdomyolysis and suggest that the protective effect of

74 (for more than 2 years in one child), and of rhabdomyolysis and weakness in the others.

75 Muscle injury (rhabdomyolysis) and subsequent deposition of myoglobin i

76 ith potential complications of coagulopathy, rhabdomyolysis, and acute kidney injury.

77 duction and rates of elevated liver enzymes, rhabdomyolysis, and cancer per 100,000 person-years was

78 owering and rates of elevated liver enzymes, rhabdomyolysis, and cancer.

79 developmental delay, stress-induced episodic rhabdomyolysis, and cardiac arrhythmias, along with seve

80 al ZFP24 gene ablation exacerbated ischemia, rhabdomyolysis, and cisplatin-associated AKI.

81 adverse drug effects such as statin-induced rhabdomyolysis, and co-administration of OATP substrates

82 in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with prog

83 receptor (RyR1) display muscle contractures, rhabdomyolysis, and death in response to elevated enviro

84 y depression, cardiac arrhythmias, seizures, rhabdomyolysis, and hypoglycemia.

85 ent disappearance of chronic cardiomyopathy, rhabdomyolysis, and muscle weakness (for more than 2 yea

86 s, in many cases, to prevent cardiomyopathy, rhabdomyolysis, and muscle weakness.

87 phy, one presented with isolated episodes of rhabdomyolysis, and one as a congenital muscular dystrop

88 pain, variable susceptibility to episodes of rhabdomyolysis, and persistent basal elevated serum crea

89 ed central core disease and exercise-induced rhabdomyolysis, and the more severe recessive phenotypes

90 elevated CK level (>380 U/L); 202 (61%) had rhabdomyolysis; and 45 (14%) had severe rhabdomyolysis (

91 ficant elevations in creatinine kinase), and rhabdomyolysis are 190, 5, and 1.6 per 100,000 patient y

92 some statins on muscle, such as myopathy and rhabdomyolysis, are rare at standard doses, and on the l

93 aracterized by encephalopathy, hypoglycemia, rhabdomyolysis, arrhythmias, and laboratory findings sug

94 on with lovastatin did not cause significant rhabdomyolysis as assessed by measuring the levels of cr

95 uly 1999 also suggested an increased risk of rhabdomyolysis associated with high doses of cerivastati

96 ation exacerbates ischemia-, cisplatin-, and rhabdomyolysis-associated AKI in vivo and cisplatin-indu

97 ions or affect the severity of cisplatin and rhabdomyolysis-associated AKI.

98 ective effects of SS-31 during cisplatin and rhabdomyolysis-associated AKI.

99 -induced oxidative stress, e.g., therapy for rhabdomyolysis-associated renal dysfunction.

100 ponse in RTECs to ischemia-, cisplatin-, and rhabdomyolysis-associated renal injury.

101 Rhabdomyolysis at admission was an independent predictor

102 Inactivating mutations cause rhabdomyolysis, autoinflammatory disease, and aberrant f

103 Among 3790 patients hospitalized for rhabdomyolysis between 2009 and 2019 in Kaiser Permanent

104 Three mouse models of acute kidney injury (rhabdomyolysis, bilateral ischemia-reperfusion injury, a

105 ncreases understanding of autosomal dominant rhabdomyolysis but also provides a diagnostic conclusion

106 nexpectedly, inactivity was not explained by rhabdomyolysis, but rather reflected the overall reduced

107 served in rat kidneys after glycerol-induced rhabdomyolysis, but the role of macrophages in rhabdomyo

108 Rhabdomyolysis can be life threatening if complicated by

109 In patients with sepsis, rhabdomyolysis, cancer, and cardiovascular disorders, th

110 hat induce acute metabolic crises, including rhabdomyolysis, cardiomyopathy, and cardiac arrhythmias,

111 The resulting muscle necrosis (rhabdomyolysis) causes acute renal injury.

112 AKI: ischemia/reperfusion, glycerol-induced rhabdomyolysis, cisplatin nephrotoxicity, and bilateral

113 requiring treatment withdrawal, particularly rhabdomyolysis, compared with simvastatin 20 mg/day plus

114 Rhabdomyolysis during EVD has been suggested to occur in

115 ents, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac

116 eak syndrome (VLS), aphasia, and evidence of rhabdomyolysis encountered at 24 mg/m2/8 d.

117 f kidney failure in patients with exertional rhabdomyolysis (ERM) has been suggested.

118 th lovastatin, does not increase the risk of rhabdomyolysis, even when administered at a high dosage

119 Two days after rhabdomyolysis, F4/80(low)CD11b(high)Ly6b(high)CD206(low

120 The rate of myopathy and rhabdomyolysis for simvastatin 80 mg, although still low

121 had rhabdomyolysis; and 45 (14%) had severe rhabdomyolysis (>=5000 U/L).

122 ificantly higher adjusted risk of exertional rhabdomyolysis (hazard ratio, 1.54; 95% CI, 1.12 to 2.12

123 of novel genetic conditions associated with rhabdomyolysis helps to shed light on hitherto unrecogni

124 Seven months after rhabdomyolysis, histologic lesions were still present bu

125 og (Drosophila) in 12 subjects with episodic rhabdomyolysis, hypoglycemia, hyperammonemia, and suscep

126 Administration of alkali, a treatment for rhabdomyolysis, improved renal function and significantl

127 case of inflammatory polymyositis leading to rhabdomyolysis in a male patient diagnosed with Crohn's

128 uman lipin 1 are a common cause of recurrent rhabdomyolysis in children.

129 Susceptibility to exertional cramps and rhabdomyolysis in myophosphorylase deficiency (McArdle's

130 The incidence of rhabdomyolysis in patients receiving 40 mg/d simvastatin

131 n implicated as the etiology of drug-induced rhabdomyolysis in several pediatric patients.

132 e-3 protein, and tubular necrosis induced by rhabdomyolysis in wild-type mice.

133 een, there was one serious adverse reaction (rhabdomyolysis) in the simvastatin group.

134 olling for known risk factors for exertional rhabdomyolysis, in a large population of active persons

135 Using a rhabdomyolysis-induced acute kidney injury (AKI) mouse m

136 of the LRRK2 KO rats are highly resistant to rhabdomyolysis-induced acute kidney injury compared with

137 The transcriptomic signature for rhabdomyolysis-induced acute kidney injury included a st

138 Specific treatment for rhabdomyolysis-induced acute kidney injury is lacking an

139 ney injury) or by IM injections of glycerol (rhabdomyolysis-induced acute kidney injury).

140 pathological role of heme and complement in rhabdomyolysis-induced acute kidney injury.

141 ubules and vessels of patients and mice with rhabdomyolysis-induced acute kidney injury.

142 anges were also observed in a mouse model of rhabdomyolysis-induced acute kidney injury; the levels o

143 Rhabdomyolysis-induced acute renal failure was induced i

144 was significantly lower under both basal and rhabdomyolysis-induced AKI in FtH(PT-/-) mice.

145 suggest an important role for macrophages in rhabdomyolysis-induced AKI progression and advocate the

146 abdomyolysis, but the role of macrophages in rhabdomyolysis-induced AKI remains unknown.

147 In a mouse model of rhabdomyolysis-induced AKI, diverse renal macrophage phe

148 ippel-Lindau protein (VHL-KO), protects from rhabdomyolysis-induced AKI.

149 tially protect surgical/trauma patients from rhabdomyolysis-induced ARF; and (3) further support the

150 elicited in intact rats by glycerol-induced rhabdomyolysis, induces ATP-dependent iron transport in

151 Drug-induced rhabdomyolysis is a common syndrome that is complex and

152 Rhabdomyolysis is a frequent disorder in EVD and seems t

153 Rhabdomyolysis is a life-threatening condition caused by

154 Rhabdomyolysis is a potentially dangerous side effect of

155 Rhabdomyolysis is a rarer and more severe form of myopat

156 Rhabdomyolysis is an acute failure of cellular homeostas

157 Rhabdomyolysis is associated with acute kidney injury an

158 Rhabdomyolysis is defined as skeletal muscle injury that

159 statin-associated elevated liver enzymes or rhabdomyolysis is not related to the magnitude of LDL-C

160 Recurrent rhabdomyolysis is often associated with genetic and meta

161 list of drugs and inciting agents that cause rhabdomyolysis is quite extensive.

162 Progression of myalgia or myositis to rhabdomyolysis is rare (one in 30-100,000 patient-years

163 Although rhabdomyolysis is rare, muscle symptoms and serum creati

164 Rhabdomyolysis is the acute breakdown of skeletal myofib

165 Severe muscle injury (rhabdomyolysis) is accompanied by the release of myoglob

166 The absolute risk increase for rhabdomyolysis may be underestimated because the codes u

167 including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevatio

168 in non-cirrhosis patients, while this was no rhabdomyolysis observed in patients on simvastatin 20 mg

169 id-lowering agents, 24 cases of hospitalized rhabdomyolysis occurred during treatment.

170 l, approximately half of the case reports of rhabdomyolysis occurred in users of this combination the

171 ower extremity paraplegia and development of rhabdomyolysis of the paraspinal muscles during the post

172 Our case describes rhabdomyolysis of the paraspinal muscles occurring after

173 rawal of cerivastatin because of deaths from rhabdomyolysis, of which 25% were related to gemfibrozil

174 tudies are needed to determine the impact of rhabdomyolysis on EVD outcome.

175 Diseases, 9th revision, diagnostic codes for rhabdomyolysis or an antihyperlipidemic adverse event, f

176 y acid oxidation defects can cause recurrent rhabdomyolysis or chronic progressive muscle weakness.

177 No episodes of rhabdomyolysis or hepatotoxicity occurred (cholesterol l

178 No cases of rhabdomyolysis or myositis occurred in either group.

179 We used mouse models of glycerol-induced rhabdomyolysis or unilateral nephrectomy with clamping i

180 ell tolerated, with no evidence of myopathy, rhabdomyolysis, or ophthalmologic abnormalities.

181 not of myalgias, creatine kinase elevations, rhabdomyolysis, or withdrawal of therapy compared with p

182 0.91), liver enzymes elevations (P = 0.34), rhabdomyolysis (P = 0.58), or new-onset diabetes mellitu

183 Incidence rates of rhabdomyolysis per 10,000 person-years of treatment, num

184 The heatstroke was complicated by seizures, rhabdomyolysis, pneumonia, renal failure, and disseminat

185 e associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy, or renal failu

186 examined the composite end point of AERs of rhabdomyolysis, proteinuria, nephropathy, or renal failu

187 Reported cases of rhabdomyolysis, proteinuria, or renal failure tended to

188 vated liver enzymes (R2 <0.001, p = 0.91) or rhabdomyolysis (R2 = 0.05, p = 0.16).

189 e elevations (RD, 0.2; 95% CI, -0.6 to 0.9), rhabdomyolysis (RD, 0.4; 95% CI, -0.1 to 0.9), or discon

190 The underlying genetic etiology of rhabdomyolysis remains elusive in a significant fraction

191 System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and Mar

192 y, which ranges in severity from myalgias to rhabdomyolysis resulting in renal failure and death.

193 Rhabdomyolysis risk was similar and low for monotherapy

194 Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents a

195 aminase elevations but rates of myopathy and rhabdomyolysis similar to lower doses of statins.

196 emic inflammation and apoptosis, haemolysis, rhabdomyolysis, smoke inhalation injury, drug nephrotoxi

197 tin was associated with much larger risks of rhabdomyolysis than other statins.

198 We previously showed in a rat model of rhabdomyolysis that redox cycling between ferric and fer

199 A variety of genetic disorders predispose to rhabdomyolysis through different pathogenic mechanisms,

200 he understanding of the genetic landscape of rhabdomyolysis to now include MLIP as a novel disease ge

201 orts of myalgia, creatine kinase elevations, rhabdomyolysis, transaminase elevations, and discontinua

202 xicity (Amanita proxima, Amanita smithiana), rhabdomyolysis (Tricholoma equestre, Russula subnigrican

203 3 patients, as well as recurrent episodes of rhabdomyolysis triggered by infections, which were relie

204 inadequately designed to assess the risk of rhabdomyolysis, until cerivastatin was removed from the

205 In an animal model of rhabdomyolysis, urinary excretion of F2-isoprostanes inc

206 e kinase levels were measured as a marker of rhabdomyolysis using a Vitros analyzer.

207 ents who presented with severe and recurrent rhabdomyolysis, usually with onset in the teenage years;

208 aking simvastatin 40 mg, pooled frequency of rhabdomyolysis was 2%, an incidence 40-fold higher than

209 number needed to treat to observe 1 case of rhabdomyolysis was 22,727 for statin monotherapy, 484 fo

210 Rhabdomyolysis was diagnosed in 3 patients with HIV infe

211 th EVD than in those without (P = .002), and rhabdomyolysis was more frequent (59% vs 19%, respective

212 Here, in a patient diagnosed with rhabdomyolysis, we detected substantial macrophage infil

213 Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH

214 At day 1 after rhabdomyolysis, when tubular injury may be reversible, t

215 evealed several patients with statin-induced rhabdomyolysis who also have metabolic muscle defects, i

216 Metabolic problems encountered can include rhabdomyolysis with acute renal failure.

217 eatine kinase in asymptomatic individuals to rhabdomyolysis with myoglobinuria, renal failure, and de

218 The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescrip